To the surprise of scientists, the most dangerous cancers of the uterine lining closely resemble the worst ovarian and breast cancers, raising the tantalizing possibility that the three deadly cancers might respond to the same drugs.
This finding, part of a major new study, is the best evidence yet that cancer will increasingly be seen as a disease defined by its genetic fingerprint rather than by the organ where it originated, researchers say.
The study of endometrial cancer -- a cancer of the uterine lining -- and another of acute myeloid leukemia, published simultaneously Wednesday by Nature and the New England Journal of Medicine, are part of a sprawling, ambitious project by the National Institutes of Health to scrutinize DNA aberrations in common cancers. The endometrial cancer and leukemia efforts alone involved more than 100 researchers who studied close to 400 endometrial tumors and 200 leukemias.
"This is exploring the landscape of cancer genomics," said David P. Steensma, a Dana-Farber Cancer Institute leukemia researcher who was not involved with the studies. "Many developments in medicine are about treatments or tests that are only useful for a certain period of time, until something better comes by. But this is something that will be useful 200 years from now. This is a landmark that will stand the test of time."
Endometrial cancer is the most common gynecological cancer in American women and strikes nearly 50,000 of them a year, killing about 8,000. Acute myeloid leukemia, the most prevalent adult leukemia, is diagnosed in about 14,000 Americans a year and kills about 10,000.
The acute myeloid leukemia study identified virtually all of the common genetic malfunctions that occur in it, providing a new foundation for assessing which cancers will be lethal unless the patient gets a risky bone marrow transplant, and which can be treated with chemotherapy alone.
Douglas Levine of Memorial Sloan Kettering Cancer Center, principal investigator on the endometrial cancer study, said the group scoured the nation for samples of this cancer.
The cancer has long been evaluated by pathologists, who examine thin slices of endometrial tumors under a microscope and put them in one of two broad categories. But the method is not ideal. In general, one category predicts a good prognosis and tumors that could be treated with surgery and radiation, while the other holds a poorer prognosis and required chemotherapy after surgery. But pathologists often disagree about how to classify the tumors and can find it difficult to distinguish between the two types, Dr. Levine said.
The new genetic analysis of hundreds of tumors found patterns of genetic aberrations that more precisely classify the tumors, dividing them into four distinct groups. About 10 percent of tumors that had seemed easily treated with the old type of exam now appear to be more deadly according to the genetic analysis and would require chemotherapy.
Another finding was that many endometrial cancers had a mutation in a gene that had been seen before only in colon cancers. The mutation disables a system for repairing DNA damage, resulting in 100 times more mutations than typically occur in cancer cells. "That was a complete surprise," Dr. Levine said.
That turned out to be good news: Endometrial cancers with the mutation had better outcomes, perhaps because the accumulating DNA damage is devastating to cancer cells.
Another surprise was that the worst endometrial tumors were so similar to the most lethal ovarian and breast cancers.
Jeff Boyd, executive director of the Fox Chase Cancer Center cancer genome institute, who was not involved with the new research, said the similarity between breast, ovarian and endometrial tumors was the best example yet of the idea that cancers are more usefully classified by their gene mutations than by where they originate. Though many scientists believe that this view is correct, Mr. Boyd said, "It is very rewarding -- I can't overstate it" to see it validated with real data.
While the genetics of endometrial cancer had gone largely unstudied until now, acute myeloid leukemia has been investigated for decades, in part because leukemia cells are so accessible. They are in the blood and bone marrow.
Using microscopes and special staining methods, researchers already knew that some chromosomal alterations were associated with a good prognosis, and others with a bad one. Patients with a good prognosis can usually be treated with chemotherapy alone, while those with a worse prognosis needed the expensive, difficult and risky treatment of last resort: a bone marrow transplant. It comes with a 10 percent death rate.
The problem was that the traditional methods for categorizing the leukemia were imprecise, said Timothy Ley of Washington University in St. Louis, who led the study with Richard Wilson, also of Washington University. Nearly half the acute myeloid leukemias had normal chromosomes. There was no good way to decide which treatment these patients needed. Some did well with chemotherapy; some did poorly.
The new study of 200 acute myeloid leukemias identified at least 260 genes that were mutated in at least two of the 200 leukemia samples. "We have the basic playbook," Mr. Ley said. "We finally know what the major pathways are and what all the major mutations look like."
The next step will be for investigators to determine which mutations lead to good or bad outcomes. And knowing which genes are mutated also allows researchers to investigate drugs that target those genes. "Within two or three years, risk assessment may be dramatically better," Mr. Ley said. "It certainly sets the stage for the next era of therapy."health - science